This Bike Lane Can Save Your Life
(Bloomberg) -- Adding bike lanes makes a city healthier—even for people who never climb on a bicycle.
Bicycle lanes have been a contentious issue in many U.S. cities, pitting motorists who say there's no room for more bikes against two-wheel enthusiasts preaching the health benefits of leaving the car at home. But if you lay down enough bike lanes, something magical begins to happen: Non-riders begin to benefit from cleaner air when the network of bike lanes gets complete enough that people start riding bikes to work instead of driving.
Less-comprehensive networks don't reduce air pollution because people use the lanes only for pleasure riding, which doesn't displace driving to work, says Babak Mohit, a post-doctoral researcher at Columbia University's Mailman School of Public Health and lead author of a study published online by the journal Injury Prevention. Additionally, bike lanes make existing riders safer and attract new riders, who get cardiovascular benefits from exercise, according to Mohit and his co-authors, Jing Gu and Peter Alexander Muennig.
Cities are embracing the idea. According to an article last year by consulting firm McKinsey & Co., “London is building 12 ‘cycle superhighways'—extra-wide lanes dedicated to bicycles.” McKinsey also cites New York, hilly San Francisco, Sao Paulo, Delhi, and even Moscow as cities that are expanding bike-lane networks.
There's math to show how cost-effective the strategy could be for public health. When New York spent about $8 million in 2015 on bike lane expansion, the cost per additional “quality-adjusted life year,” or QALY, was about $1,300, according to the Mailman paper.
A QALY, pronounced “qually,” is a standard measure of cost-benefit analysis. It takes into account the number of people who benefit from an intervention, how many years of extra life they can expect to get, and how healthy they will be during the extra years.
As it turns out, when you apply this to bike lanes, it makes them more economical per added QALY than, say, kidney dialysis, which costs over $100,000 per QALY—although not quite as cost-effective as standard vaccines, which cost in the low hundreds of dollars per QALY, Mohit said.
That's not an argument for yanking people off dialysis machines and using the money to build bike lanes, but it does support the idea that “investments in bike lanes are more cost-effective than the majority of preventive approaches used today,” the paper states.
“While we use NYC as an example, our intent is to provide a much more generalisable model, such that localities can estimate the return on their investment in bike paths,” the authors write.
To contact the author of this story: Peter Coy in New York at pcoy3@bloomberg.net.
To contact the editor responsible for this story: David Rovella at drovella@bloomberg.net.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.